The Impact of IL-17A Inhibition in Rheumatic and Musculoskeletal Diseases: Current Insights and Future Prospects

Ramiro S, Schett G, Marzo-Ortega H, Schmidt WA (2025)

Publication Type: Journal article, Review article

Publication year: 2025

Journal

Rheumatology and Therapy Adis Open Access

Article Number: 637829

DOI: 10.1007/s40744-025-00754-w

Abstract

Interleukin-17A (IL-17A) plays a pivotal role in many rheumatic immune-mediated inflammatory diseases. Targeting the IL-17 pathway has transformed the way psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) are managed, with a number of IL-17A inhibitors now available for treating rheumatic and musculoskeletal diseases. This narrative review will describe the opportunities presented by novel imaging techniques in understanding the metabolic and mechanical changes that characterize the pathogenesis of PsA and axSpA. It will look at the current consensus definitions of early disease in PsA and axSpA, present evidence for the benefit of early treatment, and highlight the gaps in current knowledge. Finally, it will describe novel treatment targets to address the unmet needs in giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) and discuss the potential role of IL-17A inhibition in treating GCA and PMR.

Authors with CRIS profile

Georg Schett Lehrstuhl für Innere Medizin III

Involved external institutions

Leiden University NL Netherlands (NL) University of Leeds GB United Kingdom (GB) Vivantes - Netzwerk für Gesundheit GmbH DE Germany (DE)

How to cite

APA:

Ramiro, S., Schett, G., Marzo-Ortega, H., & Schmidt, W.A. (2025). The Impact of IL-17A Inhibition in Rheumatic and Musculoskeletal Diseases: Current Insights and Future Prospects. Rheumatology and Therapy. https://doi.org/10.1007/s40744-025-00754-w

MLA:

Ramiro, Sofia, et al. "The Impact of IL-17A Inhibition in Rheumatic and Musculoskeletal Diseases: Current Insights and Future Prospects." Rheumatology and Therapy (2025).

BibTeX: Download